Chiron/Searle Tifacogin Will Begin Two-Year, 1,500 Patient Trial In Sepsis
Executive Summary
Chiron will initiate a pivotal, 1,500 patient trial of tifacogin in sepsis in the first half of the year, Chiron Chairman & CEO Sean Lance said during a Feb. 8 conference call announcing the company's sales and earnings for 1999.
You may also be interested in...
Pharmacia takes a shot at sepsis
"You will be hearing more...in the fall" about the potential sepsis agent tifacogin, Pharmacia CFO Chris Coughlin tells the Goldman Sachs conference June 14. "It is a high risk area" and "we tend to be conservative and not try to tout these things too early," Coughlin says. The recombinant protein tissue factor pathway inhibitor, being developed in collaboration with Chiron, entered Phase III in mid-2000; interim data from the two-year, 1,500-patient trial will be analyzed around year-end (1"The Pink Sheet" Feb. 14, 2000, p. 33)
Pharmacia takes a shot at sepsis
"You will be hearing more...in the fall" about the potential sepsis agent tifacogin, Pharmacia CFO Chris Coughlin tells the Goldman Sachs conference June 14. "It is a high risk area" and "we tend to be conservative and not try to tout these things too early," Coughlin says. The recombinant protein tissue factor pathway inhibitor, being developed in collaboration with Chiron, entered Phase III in mid-2000; interim data from the two-year, 1,500-patient trial will be analyzed around year-end (1"The Pink Sheet" Feb. 14, 2000, p. 33)
Detrol Sales Potential Could Be $1 Bil. With Once-Daily Indication, P&U Says
The sales potential of Pharmacia & Upjohn's overactive bladder treatment Detrol (tolterodine) could be up to half a billion dollars greater than previous projections, pending approval of a once-daily formulation.